Ameritas Advisory Services’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.4K Sell
137
-160
-54% -$9.36K ﹤0.01% 1469
2026
Q2
$11.4K Buy
+297
New +$7.78K ﹤0.01% 1451
2024
Q3
– Sell
-20,000
Closed -$389K – 937
2024
Q2
$389K Sell
20,000
-5,417
-21% -$142K 0.01% 654
2024
Q1
$954K Buy
+25,417
New +$1.12M 0.04% 390
2023
Q4
– Sell
-25,422
Closed -$1.05M – 841
2023
Q3
$1.05M Buy
+25,422
New +$1.32M 0.05% 330
2023
Q2
– Sell
-25,426
Closed -$1.38M – 2372
2023
Q1
$1.38M Sell
25,426
-3
-0% -$140 0.07% 259
2022
Q4
$927K Sell
25,429
-2
-0% -$65 0.04% 371
2022
Q3
$724K Buy
25,431
+11
+0% +$419 0.04% 355
2022
Q2
$1.15M Hold
25,420
– – 0.07% 266
2022
Q1
$1.93M Hold
25,420
– – 0.07% 216
2021
Q4
$3.79M Buy
+25,420
New +$3.89M 0.14% 124

Other funds holding TXG

Ameritas Advisory Services's TXG Position: Q3 2026 in Review

Ameritas Advisory Services reduced its 10x Genomics (TXG) stake by 54% in Q3 2026, selling an estimated $9.36K and leaving 137 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

Ameritas Advisory Services first reported a position in TXG in Q4 2021 and has held it in 11 quarters since. The position peaked at $3.79M in Q4 2021. 491 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Ameritas Advisory Services held 137 shares of 10x Genomics worth $12.4K as of Q3 2026.
  • Ameritas Advisory Services sold 160 10x Genomics shares in Q3 2026, an estimated $9.36K.
  • 10x Genomics made up ﹤0.01% of Ameritas Advisory Services's portfolio in Q3 2026, its #1469 holding.
  • Ameritas Advisory Services first reported a position in 10x Genomics in Q4 2021 and has held it in 11 quarters since.
  • Ameritas Advisory Services's 10x Genomics position peaked at $3.79M in Q4 2021.
  • 491 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Ameritas Advisory Services's 13F filing for Q3 2026, filed 12 Nov 2026.